PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Nature. Author manuscript; available in PMC 2013 May 22.
Published in final edited form as:
PMCID: PMC3504651
NIHMSID: NIHMS404748

Progressive degeneration of human neural stem cells caused by pathogenic LRRK2

Abstract

Nuclear architecture defects have been shown to correlate with the manifestation of a number of human diseases as well as aging1-4. It is then plausible that diseases whose manifestations correlate with aging might be connected to the appearance of nuclear aberrations over time. We decided to evaluate nuclear organization in the context of aging-associated disorders by focusing on a Leucine Rich Repeat Kinase 2 (LRRK2) dominant mutation (G2019S) shown to associate with familial and sporadic Parkinson’s Disease (PD), as well as impairment of adult neurogenesis in mice5. Here, we report on the generation of PD patient-derived induced pluripotent stem cells (iPSCs) and the implications of LRRK2(G2019S) in human neural stem cell (NSC) populations. Mutant NSCs showed increased susceptibility to proteasomal stress as well as passage-dependent deficiencies in clonal expansion and neuronal differentiation. Disease phenotypes were rescued by targeted correction of the LRRK2(G2019S) mutation with its wild-type counterpart in PD-iPSCs and recapitulated upon targeted knock-in of LRRK2(G2019S) in human embryonic stem cells (hESCs). Analysis of human brain tissue showed nuclear envelope impairment in clinically diagnosed Parkinson’s patients. Altogether, our results identify the nucleus as a previously unknown cellular organelle in Parkinson’s pathology and may help open new avenues for PD diagnoses as well as potential development of therapeutics targeting this fundamental cell structure.

To study the role that the nuclear envelope might have during aging-related neurodegenerative processes we chose to focus our attention on Parkinson’s disease (PD), the second most prevalent neurodegenerative disease among aging individuals. LRRK2 is a large multidomain protein bearing kinase activity10 whose mutations correlate with inherited and sporadic PD10, 11. Specifically, G2019S mutation leads to an increase in LRRK2 kinase activity correlating with the manifestation of disease3,10-13. However, the molecular and cellular implications of LRRK2(G2019S) during PD manifestation and progression remain elusive.

To this end, we first decide to evaluate potential novel interactions. Flag-tagged version of LRRK2(G2019S) and subsequent MudPIT analysis led to the identification of unreported nuclear components in LRRK2(G2019S)-containing protein complexes (Supplementary Fig. 2a and b and Supplementary Table 1). Furthermore, LRRK2(G2019S) overexpression resulted in deformed nuclei with a pedal-like structure (Supplementary Fig. 2c-d).

The fact that LRRK2(G2019S) leads to impaired adult neurogenesis in mice 5, led us to take advantage of iPSC technologies and their potential for directed differentiation into specific human cell lineages (Supplementary Figs. 3 and 4). Differentiation of iPSCs into neural progenitors followed by serial passaging resembling cellular “aging”14 showed progressive deterioration of nuclear architecture in mutant but not in wild-type NSCs (ipsNSCs-LRRK2(G2019S) and ipsNSCs-wt respectively). Nuclear aberrations started to manifest by passage 14 and progressively resulted in compartmentalized pedal-like nuclei (Fig. 1a-f, Supplementary Figs. 5c, 6 and 7). Staining for Lamin B1 in late-passage differentiated as well as LRRK2(G2019S)-overexpressing wild-type NSCs (e.g. passage 19), demonstrated a markedly enlarged nuclear area, accompanied by a significant decrease in nuclear circularity, in ipsNSCs-LRRK2(G2019S) (Fig.1c-e, Supplementary Fig. 5c and Supplementary Fig. 8a). Noticeably, late passage ipsNSCs-LRRK2(G2019S) exhibited local loss of Lamin B1 and B2 at specific folds of the nuclear envelope (Fig. 1c,f and g, and Supplementary Figs 6e and 7) whereas all other examined nuclear components remained correctly localized (Fig. 1f and Supplementary Figs. 6e and 7). Co-immunoprecipitation experiments revealed that ectopically expressed LRRK2(G2019S) associated in protein complexes with both, Lamin B1 and Lamin B2 (Fig. 1h). Furthermore, increased phosphorylation of Lamin B1 and Lamin B2 was observed in late passage ipsNSC-LRRK2(G2019S) (Supplementary Fig. 8b), suggesting that excessive LRRK2 kinase activation may directly or indirectly stimulate phosphorylation of B-type lamins in NSCs. Lastly, analysis of mitochondrial structure, an organelle frequently implicated in PD pathogenesis10, demonstrated the normal expression of the outer mitochondrial membrane receptor TOM20 as well as the mitochondrial heat shock protein HSP60 in both NSCs-wt and NSCs-LRRK2(G2019S) (Supplementary Fig. 9).

Fig.1
LRRK2(G2019S) mutation results in progressive deterioration of nuclear architecture in ipsNSCs

We next wondered whether LRRK2(G2019S)-elicited nuclear defects contributed to epigenetic alterations such as those observed during cellular aging1, 2, 15. Fluorescence in situ hybridization revealed a dramatic increase of centromeric signals accompanied by reorganization of centromeric, but not telomeric, heterochromatin in passage 15 ipsNSCs-LRRK2(G2019S) (Supplementary Fig. 10a). Genome-wide epigenetic analysis demonstrated passage-dependent differences in global H3K4me3 modifications, an epigenetic mark associated with human neuronal aging16, at the analyzed promoter regions (Fig. 2a and Supplementary Fig. 10b). At passage 15, 437 genes in ipsNSCs-LRRK2(G2019S) displayed ≥5-fold enrichment for the epigenetic mark H3K4me3 as compared to ipsNSCs-wt whereas no significant differences were observed when comparing undifferentiated iPSCs. Interestingly, most of these genes were associated with neurogenesis and neural function (Supplementary Table 2).

Fig. 2
LRRK2(G2019S) mutant ipsNSCs show deficiency in clonal expansion, spontaneous neuronal differentiation, and exhibit enhanced susceptibility to proteasomal stress-induced apoptosis

These results led us to hypothesize that LRRK2(G2019S) might progressively affect other in vitro NSC functions such as clonal expansion and neural differentiation. Newly generated ipsNSCs-wt and ipsNSCs-LRRK2(G2019S) were similarly capable of both clonal expansion and neural differentiation, whereas only ipsNSCs-wt retained clonogenic and differentiation capacity upon extensive passaging (≥14) (Fig. 2b-d and Supplementary Fig. 8c). Strikingly, passage 16-17 ipsNSCs-LRRK2(G2019S) failed to give rise to MAP2+ (or Tuj1+) cells and resulted in aberrant non-neuronal cellular morphologies upon differentiation (Fig. 2c and d and Supplementary Figs. 8c, 11a and b). Injection of proteasome inhibitors into animal brains has been shown to recapitulate PD phenotypes17. Interestingly, treatment of NSCs with the proteasome inhibitor MG132 resulted in increased apoptosis in ipsNSCs-LRRK2(G2019S) as compared to their wild-type counterparts in a passage-independent manner (Fig. 2e and Supplementary Fig. 11c and d).

To further validate that the observed cellular phenotypes were related to NSCs carrying the LRRK2(G2019S) mutation, we evaluated different somatic cell types as well as generated two different unbiased cellular systems, an isogenic control iPSC line by targeted correction of the LRRK2(G2019S) mutation as well as the reversal by specific knock-in of LRRK2(G2019S) into human Embryonic Stem Cells (hESCs)18-21 (Fig. 3a-c and Supplementary Figs. 12 and 13). Contrary to LRRK2(G2019S) NSCs, long-term in vitro culture of differentiated somatic cell populations, other than NSCs, did not result in misshapen nuclei (Supplementary Fig. 15). LRRK2(G2019S)-corrected iPSC differentiation (c-ipsNSCs-LRRK2(G2019S), resulted in the rescue of aberrant cellular phenotypes as compared to the respective uncorrected controls (Fig. 3d-g). Conversely, LRRK2(G2019S) knock-in in ESCs resulted in the progressive appearance of disrupted nuclear architecture, compromised clonal expansion, impaired neural differentiation and increased susceptibility to proteasomal stress upon differentiation into NSCs [esNSC-LRRK2(G2019S)] (Fig. 3h-k and Supplementary Figs. 13 and 14). Altogether, our results suggested a specific role for LRRK2(G2019S) during the manifestation of passage-dependent NSC abnormal phenotypes and highlighted the nucleus as a potential novel organelle affected in PD.

Fig. 3
Phenotypic analyses of isogenic iPSC and ESC lines in the presence or absence of the LRRK2(G2019S) mutation

Since LRRK2(G2019S) displays enhanced Ser/Thr protein kinase activation that correlates with its pathogenic role in PD10, 11, 22-24, we investigated whether kinase activity correlated with nuclear degeneration (Supplementary Fig. 16). Our results suggested that cell passaging further enhanced LRRK2(G2019S)-mediated phosphorylation of a number of different substrates including 4E-BP1, a known LRRK2 target 24 (Fig. 4a and Supplementary Fig. 16a-b). Interestingly, Ser935 phosphorylation, an indicator for LRRK2 activation12, 22, 25, 26, was increased in passage 15 ipsNSCs-LRRK2(G2019S) relative to total LRRK2 levels (Fig. 4a and Supplementary Fig. 16c).

Fig. 4
Inhibition of LRRK2 kinase activity rescues LRRK2(G2019S)-associated phenotypic defects in NSCs and morphological analysis of nuclear envelope in PD brain slices

Chemical inhibition has been previously shown to protect against LRRK2 associated toxicity in vitro and in vivo13, 22. Accordingly, treating late-passage ipsNSCs-LRRK2(G2019S) with LRRK2-In-112, 22 resulted in reduced phosphorylation of LRRK2 downstream targets and significantly rescued the aberrant cellular parameters observed in late-passage ipsNSCs-LRRK2(G2019S), (Fig. 4b-f, Supplementary Fig. 6a-c, and Supplementary Movie 1). Microarray analysis demonstrated that 5-day incubation of passage 14 esNSCs-LRRK2(G2019S) with LRRK2-In-1 was sufficient to restore a gene expression signature similar to that of wild-type esNSCs and significantly different from untreated controls (Fig. 4g; Supplementary Table 3). Further studies on cross-talking signaling pathways suggested that LRRK2-In-1 was capable of restoring both nuclear morphology and colony-like growth in late passage ipsNSCs-LRRK2(G2019S), whereas, LY294002, a PI3K inhibitor, partially rescued nuclear morphology (Supplementary Fig. 16c and 17).

Lastly, we investigated nuclear morphology in post-mortem human brain samples. Lamin B1 immunostaining demonstrated a high proportion of cells displaying altered nuclear morphologies within the hippocampal dentate gyrus, but not in non-neurogenic areas such as cortex regions, in all the analyzed LRRK2(G2019S)-PD patients’ samples as compared to their respective age-matched controls (78.82%±6.28 and 16.49%±4.26 respectively) (Fig. 4h, Supplementary Table 5 and Supplementary Fig. 18). Interestingly, nuclear aberrations were not only present in LRRK2(G2019S) but also in several idiopathic PD human brain samples (47.28%±4.217). Of note, control samples also displayed nuclear disruption to a certain extent, which might be potentially due to the described association of physiological aging and the nuclear envelope27 (Fig. 4h and Supplementary Fig. 18). Whereas due to the reduced number of samples (n=5) we cannot conclude that the above mentioned phenotypes have a 100% penetrance in all PD patients, these results indicate the possibility that dysfunctional NSC pools, and/or their respective neuronal derivatives at early stages of maturation, might contribute to the hippocampal and subventricular zone-related age-dependent non-motor symptoms, including depression, anxiety and hyposmia, associated with LRRK2(G2019S)-bearing individuals and PD5, 29.

Altogether, LRRK2(G2019S)-elicited aberrant phenotypic manifestations seemed particularly prominent in human NSC populations and were more noticeable at late passages. Of most relevance, our studies further indicate the suitability of iPSC-based models of disease and aging not only for the in vitro recapitulation of known disease phenotypes, as extensively described, but also as a platform for discovery and study of otherwise novel and elusive cell parameters and populations30 (Supplementary Fig. 1). Furthermore, through the analysis of human brain samples, our study demonstrates that these cellular aberrations can also be found in vivo. The fact that this validation was only possible in human samples once a reliable iPSC in vitro system was employed further highlights the potential of patient-specific iPSCs, not only for disease modeling but, most importantly, for the advancement of disease pathology knowledge.

Method summary

iPSC generation

Parkinson’s disease fibroblasts were obtained from Telethon Genetic Biobank Network and brain patient samples from the Biobank of hospital clinic (IDIBAPS) in Barcelona. Normal fibroblasts were purchased from Coriell Cell Repository. Fibroblasts were reprogrammed with retroviruses expressing OCT4, SOX2, KLF4. The generated iPSC lines were maintained in hESC medium on iMEF feeder cells or in mTeSR on Matrigel 1, 18.

Targeted gene correction in iPSCs-LRRK2(G2019S) and generation of isogenic hESC line with a LRRK2(G2019S) mutation

Gene targeting in iPSCs-LRRK2(G2019S) and H9 ESCs were performed using an HDAdV-based method 18-20.

Statistical analysis

Results are presented as mean±s.d. or mean±s.e.m. for at least three independent biological replicates. Comparisons were performed with student’s t-test. Distributions of nuclear area and nuclear envelope (NE) circularity were analyzed with the Kolmogorov-Smirnov test.

Supplementary Material

video

Acknowledgements

We would like to thank K. Mitani, P. Ng, A. Lieber, Y. Imai, M. A. Miyawaki, Filocamo, S. Goldwurm, Telethon Genetic Biobank Network and Neurological Tissue Bank of the Biobank-Hospital Clínic-IDIBAPS for kindly providing human brain tissue, F. Gage, M. Hetzer, J. Yao, Y. Mu, D. Yu, E. Gelpí, G. Bai, and Z.J. Liu for helpful discussions, M. Joens and J. Fitzpatrick of the Waitt Advanced Biophotonics Core Facility for performing TEM analysis, M. Marti and C. Gomez for teratoma and karyotyping analysis, F. Osakada for statistics analysis, and M. Schwarz, P. Schwarz, and L. Laricchia-Robbio for administrative help. G.H.L. was supported by “Thousand Young Talents” program of China, National Laboratory of Biomacromolecules, “Strategic Priority Research Program” of the Chinese Academy of Sciences. J.Q. was partially supported by an AFAR/Ellison Medical Foundation postdoctoral fellowship. K.S. was partially supported by a Uehara Memorial Foundation research fellowship. E.N. was partially supported by an F.M. Kirby Foundation postdoctoral fellowship. B.R. was supported by NIH (ES017166) and LICR. J.Y. was supported by a NIH grant (P41 RR011823). J.C.I.B. was supported by grants from the Glenn Foundation, G. Harold and Leila Y. Mathers Charitable Foundation, Sanofi, The California Institute of Regenerative Medicine, Ellison Medical Foundation, Helmsley Charitable Trust, MINECO, and Fundacion Cellex.

Footnotes

Author’s contribution GHL, JQ, KS prepared the figures, designed and performed all in vitro experiments. EN and NM designed and performed in vivo experiments. AG, JK, RPS, XX, WZ, YL and CRE provided technical assistance. ID performed teratoma studies. FY and ML performed mRNA analysis. SR performed and provided cell cycle analysis expertise. BR, UW and AK performed and analyzed epigenetic studies. JT and JYIII provided reagents and designed aging studies. GHL, JQ, KS, EN, ISM and JCIB wrote the manuscript. Reprints, permissions, correspondence and requests for materials should be addressed to the attention of GHL and JCIB.

References

1. Liu GH, et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature. 2011;472:221–225. [PMC free article] [PubMed]
2. Dechat T, et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008;22:832–853. [PubMed]
3. Kudlow BA, Kennedy BK, Monnat RJ., Jr. Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol. 2007;8:394–404. [PubMed]
4. Worman HJ, Ostlund C, Wang Y. Diseases of the nuclear envelope. Cold Spring Harb Perspect Biol. 2010;2:a000760. [PMC free article] [PubMed]
5. Winner B, et al. Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis. 2011;41:706–716. [PMC free article] [PubMed]
6. Chang KH, et al. Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal death. Mol Biol Cell. 2011;22:1452–1462. [PMC free article] [PubMed]
7. Tran D, Chalhoub A, Schooley A, Zhang W, Ngsee JK. Amyotrophic Lateral Sclerosis Mutant VAPB Causes a Nuclear Envelope Defect. J Cell Sci. 2012 [PubMed]
8. Padiath QS, et al. Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet. 2006;38:1114–1123. [PubMed]
9. Woulfe JM. Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress. Neuropathol Appl Neurobiol. 2007;33:2–42. [PubMed]
10. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease. Nat Rev Neurosci. 2010;11:791–797. [PMC free article] [PubMed]
11. Cookson MR, Bandmann O. Parkinson’s disease: insights from pathways. Hum Mol Genet. 2010;19:R21–27. [PMC free article] [PubMed]
12. Deng X, et al. Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2. Nat Chem Biol. 2011;7:203–205. [PMC free article] [PubMed]
13. Lee BD, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease. Nat Med. 2010;16:998–1000. [PMC free article] [PubMed]
14. Li W, et al. Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc Natl Acad Sci U S A. 2011;108:8299–8304. [PubMed]
15. Krishnan V, et al. Histone H4 lysine 16 hypoacetylation is associated with defective DNA repair and premature senescence in Zmpste24-deficient mice. Proc Natl Acad Sci U S A. 2011;108:12325–12330. [PubMed]
16. Cheung I, et al. Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. Proc Natl Acad Sci U S A. 2010;107:8824–8829. [PubMed]
17. Xie W, et al. Proteasome inhibition modeling nigral neuron degeneration in Parkinson’s disease. J Neurochem. 2010;115:188–199. [PubMed]
18. Liu GH, et al. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell. 2011;8:688–694. [PMC free article] [PubMed]
19. Suzuki K, et al. Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors. Proc Natl Acad Sci U S A. 2008;105:13781–13786. [PubMed]
20. Li M, et al. Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCs. Cell Res. 2011 [PMC free article] [PubMed]
21. Aizawa E, et al. Efficient and accurate homologous recombination in hESCs and hiPSCs using helper-dependent adenoviral vectors. Mol Ther. 2012;20:424–431. [PubMed]
22. Rudenko IN, Chia R, Cookson MR. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson’s disease? BMC Med. 2012;10:20. [PMC free article] [PubMed]
23. Kanao T, et al. Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. Hum Mol Genet. 2010;19:3747–3758. [PubMed]
24. Gehrke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature. 2010;466:637–641. [PMC free article] [PubMed]
25. Nichols RJ, et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization. Biochem J. 2010;430:393–404. [PMC free article] [PubMed]
26. Dzamko N, et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J. 2010;430:405–413. [PMC free article] [PubMed]
27. Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science. 2006;312:1059–1063. [PMC free article] [PubMed]
28. Coffinier C, et al. Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons. Mol Biol Cell. 2011;22:4683–4693. [PMC free article] [PubMed]
29. Poulopoulos M, et al. Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD. J Mol Neurosci. 2012;47:139–143. [PMC free article] [PubMed]
30. Tiscornia G, Vivas EL, Belmonte JC. Diseases in a dish: modeling human genetic disorders using induced pluripotent cells. Nat Med. 2011;17:1570–1576. [PubMed]